U.S. markets closed

Hoth Therapeutics, Inc. (HOTH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.3600+0.0500 (+3.82%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close1.3100
Open1.2700
Bid1.3000 x 3000
Ask1.3800 x 800
Day's Range1.2700 - 1.3750
52 Week Range1.2660 - 4.9600
Volume376,553
Avg. Volume4,514,950
Market Cap32.466M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.5820
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus
    PR Newswire

    Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today it plans to host a virtual information session on its pipeline product, HT-005 Z-Pods™, a novel endocannibinoid treatment for patients with Cutaneous Lupus Erythematosus (CLE), on Tuesday, May 18th at 11:00am ET for interested shareholders. Adam Friedman, MD, FAAD and Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences, who has worked on the development of this novel therapeutic, will provide an overview on the burden of cutaneous lupus, the gap in care for diagnosed patients, and how HT-005 Z-Pods™ is designed to address both treatment and quality of life concerns for CLE patients. Dr. Friedman will also provide a brief overview of the proof-of-concept efficacy data from an animal study.

  • Hoth Therapeutics and Virginia Commonwealth University Expand Research Agreement for COVID-19 Therapeutic
    PR Newswire

    Hoth Therapeutics and Virginia Commonwealth University Expand Research Agreement for COVID-19 Therapeutic

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

  • Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers
    PR Newswire

    Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers

    Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple orphan diseases, which are rare diseases that affect less than 200,000 people in the US. HT-KIT targets a shared cell signaling pathway that may have therapeutic potential for multiple rare cancers, including: